Abcam, ab307697, Anti-ALDH1L1 antibody [EPR25443-103] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ALDH1L1 antibody. Carrier free. Suitable for mIHC, WB, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25443-103,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat,
Applications:mIHC, IHC-P, WB, Flow Cyt (Intra), ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ALDH1L1 also known as 10-formyltetrahydrofolate dehydrogenase plays an important role as a metabolic enzyme involved in folate metabolism. Typically ALDH1L1 has a molecular mass of around 100 kDa. You can find this protein expressed strongly in the liver and brain particularly in astrocytes where it serves as a marker for these star-shaped glial cells. The expression of ALDH1L1 indicates its significant presence in these tissues helping researchers identify and study astrocyte function more effectively.
Biological function summary
ALDH1L1 is involved in the one-carbon metabolism pathway contributing to the conversion of formyl groups into CO2. This reaction aids in regulating cellular homeostasis and energy production. Within the biological context ALDH1L1 works independently and does not form a large complex but efficiently interacts with other enzymes involved in folate transformations. Its activity ensures proper folate cycle functioning supporting DNA synthesis and repair.
Pathways
ALDH1L1 importantly integrates into the folate metabolism pathway supporting detoxification and nucleotide biosynthesis. In this pathway ALDH1L1 interacts with the MTHFD1 protein to maintain the balance of one-carbon units necessary for nucleic acid synthesis. Furthermore ALDH1L1 interplays within the methionine cycle influencing the methylation processes important for gene expression and epigenetic regulation.
ALDH1L1 has associations with neurological conditions particularly Alzheimer's disease and glioblastoma. Changes in ALDH1L1 expression levels have implication in the progression of these diseases. In the context of glioblastoma researchers observe altered ALDH1L1 expression alongside traditional astrocyte markers like GFAP in the tumor microenvironment. Understanding ALDH1L1's role in these conditions could provide insights for developing therapeutic strategies targeting astrocyte behavior.